Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D. Emde-Rajaratnam M, et al. Among authors: de veirman k. Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023. Front Immunol. 2023. PMID: 38035078 Free PMC article.
Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.
De Veirman K, De Beule N, Maes K, Menu E, De Bruyne E, De Raeve H, Fostier K, Moreaux J, Kassambara A, Hose D, Heusschen R, Eriksson H, Vanderkerken K, Van Valckenborgh E. De Veirman K, et al. Among authors: de bruyne e, de raeve h, de beule n. Cancer Immunol Res. 2017 Oct;5(10):839-846. doi: 10.1158/2326-6066.CIR-17-0192. Epub 2017 Sep 13. Cancer Immunol Res. 2017. PMID: 28903971
Metabolic Features of Multiple Myeloma.
El Arfani C, De Veirman K, Maes K, De Bruyne E, Menu E. El Arfani C, et al. Among authors: de bruyne e, de veirman k. Int J Mol Sci. 2018 Apr 14;19(4):1200. doi: 10.3390/ijms19041200. Int J Mol Sci. 2018. PMID: 29662010 Free PMC article. Review.
The genetic landscape of 5T models for multiple myeloma.
Maes K, Boeckx B, Vlummens P, De Veirman K, Menu E, Vanderkerken K, Lambrechts D, De Bruyne E. Maes K, et al. Among authors: de bruyne e, de veirman k. Sci Rep. 2018 Oct 9;8(1):15030. doi: 10.1038/s41598-018-33396-w. Sci Rep. 2018. PMID: 30301958 Free PMC article.
Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.
De Veirman K, Menu E, Maes K, De Beule N, De Smedt E, Maes A, Vlummens P, Fostier K, Kassambara A, Moreaux J, Van Ginderachter JA, De Bruyne E, Vanderkerken K, Van Valckenborgh E. De Veirman K, et al. Among authors: de smedt e, de bruyne e, de beule n. Cancer Lett. 2019 Feb 1;442:233-241. doi: 10.1016/j.canlet.2018.11.002. Epub 2018 Nov 9. Cancer Lett. 2019. PMID: 30419344
Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.
Oudaert I, Satilmis H, Vlummens P, De Brouwer W, Maes A, Hose D, De Bruyne E, Ghesquière B, Vanderkerken K, De Veirman K, Menu E. Oudaert I, et al. Among authors: de bruyne e, de brouwer w, de veirman k. J Exp Clin Cancer Res. 2022 Feb 1;41(1):45. doi: 10.1186/s13046-022-02250-3. J Exp Clin Cancer Res. 2022. PMID: 35105345 Free PMC article.
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.
Vlummens P, Verhulst S, De Veirman K, Maes A, Menu E, Moreaux J, De Boussac H, Robert N, De Bruyne E, Hose D, Offner F, Vanderkerken K, Maes K. Vlummens P, et al. Among authors: de bruyne e, de boussac h, de veirman k. Front Cell Dev Biol. 2022 Jun 8;10:879057. doi: 10.3389/fcell.2022.879057. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35757005 Free PMC article.
55 results